Log In
Print
BCIQ
Print
Print this Print this
 

NPSP790, SB-423557

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionSmall molecule antagonist of the calcium receptor
Molecular Target Calcium sensing receptor (CaSR)
Mechanism of ActionCalcium-sensing receptor (CaSR) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Metabolic (unspecified)
Indication DetailsTreat autosomal dominant hypocalcaemia with hypercalciuria (ADHH)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$5,200.0M

$2,250.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today